InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI and New York, NY, USA. Source
No articles found.
ACS Global, Inc. engages in the collection, processing, and long-term storage of s...
ACS Global, Inc. engages in the collection, pro...
Patient Access Solutions Inc provides administrative, management, and facility ser...
Patient Access Solutions Inc provides administr...
Cortexyme is a biopharmaceutical company developing therapeutics based on data sup...
Cortexyme is a biopharmaceutical company develo...
Catalyst is focused on developing novel medicines to address serious medical condi...
Catalyst is focused on developing novel medicin...
miRagen Therapeutics, Inc., is a clinical stage biopharmaceutical company discover...
miRagen Therapeutics, Inc., is a clinical stage...
Fennec Pharmaceuticals, Inc., (NASDAQ: FENC; TSX: FRX) is a specialty pharmaceutic...
Fennec Pharmaceuticals, Inc., (NASDAQ: FENC; TS...
Morphic Therapeutic is leading the development of a new generation of oral integri...
Morphic Therapeutic is leading the development ...
TG Therapeutics is a biopharmaceutical company focused on the acquisition, develop...
TG Therapeutics is a biopharmaceutical company ...
Caladrius is a clinical-stage biopharmaceutical company committed to the developme...
Caladrius is a clinical-stage biopharmaceutical...
Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical c...
Corbus Pharmaceuticals Holdings, Inc. is a Phas...
Join the National Investor Network and get the latest information with your interests in mind.